Cipla's wholly-owned subsidiary -- InvaGen Pharmaceuticals, Inc. (InvaGen), has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility in Hauppauge, Long Island, New York, USA, indicating the closure of the inspection.
Earlier, InvaGen had received two inspectional observations in Form 483 from USFDA for said manufacturing facility. The USFDA had conducted a Pre-Approval Inspection (PAI) at the said manufacturing facility from February 2, 2026 to February 9, 2026.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
